Order before 3pm, dispatched same day
Order before 3pm, dispatched same day Research Use Only
Pay by Card / Apple Pay
99% Purity Money Back Guarantee Retatrutide Now Available

Metabolic Research Stack: Tirzepatide + Tesamorelin + AOD Protocol

Back to library
peptide

Metabolic Research Stack: Tirzepatide + Tesamorelin + AOD Protocol

10 min read
RESEARCH STACK
METABOLIC RESEARCH
METABOLIC RESEARCH STACK
⚠️ CONTAINS POM
✅ RESEARCH CHEMICAL

⚠️ PRESCRIPTION-ONLY MEDICINE NOTICE

This stack contains Tirzepatide, a dual GLP-1R/GIP-R agonist classified as a Prescription Only Medicine (POM) in the United Kingdom under the Human Medicines Regulations 2012. Tirzepatide (Mounjaro®) requires a valid prescription from a licensed healthcare professional for any clinical use. Pure Grade Labs supplies Tirzepatide strictly as a research chemical for laboratory investigation only — not for human administration. No medical claims are made. Researchers must obtain all required institutional and regulatory approvals before working with prescription-status compounds.

Research Use Only. All components of the Metabolic Research Stack are sold strictly as research chemicals for in vitro and laboratory study. This article summarises published preclinical and clinical literature and does not constitute medical advice or a treatment recommendation.

Metabolic Research Stack: Tirzepatide + Tesamorelin + AOD-9604 Protocol

The Metabolic Research Stack brings together three compounds that approach fat metabolism from distinct mechanistic angles: Tirzepatide (dual incretin receptor agonism targeting appetite and insulin), Tesamorelin (GHRH analogue specifically studied for visceral adipose tissue reduction), and AOD-9604 (GH C-terminal fragment with direct β3-adrenergic receptor activity). Each operates through an independent pathway — making this a mechanistically non-redundant research combination for studying multi-axis metabolic regulation in preclinical models.

Key Takeaways

  • Tirzepatide: Dual GLP-1R/GIP-R agonist — suppresses appetite (hypothalamus), enhances insulin secretion (pancreas), reduces systemic inflammation (POM in UK)
  • Tesamorelin: GHRH analogue (CAS: 218949-48-5) — GHRH-R/Gαs/cAMP → ↑GH → selective visceral fat reduction; FDA-approved (Egrifta) for HIV lipodystrophy
  • AOD-9604: HGH C-terminal fragment (176-191 region, CAS: 221231-10-3) — direct β3-AR agonism → lipolysis independent of IGF-1 elevation
  • Three independent pathways: incretin axis / GH axis / adrenergic lipolysis — mechanistic non-redundancy is the stack’s research rationale
  • SURMOUNT-1 (Tirzepatide): 22.5% mean weight loss at 72 weeks in obese subjects; METAOD005 (AOD): 1 mg/day optimal dose in Phase IIb
  • No published co-administration trial exists for this combination — research hypothesis awaiting formal preclinical study
22.5%
Weight Loss
Tirzepatide SURMOUNT-1 (72 wk)
18%
VAT Reduction
Tesamorelin vs placebo (26 wk)
1 mg/day
AOD Optimal Dose
METAOD005 Phase IIb (n=300+)
3
Independent Pathways
Incretin · GH axis · β3-AR

Pure Grade Labs supplies the Metabolic Research Stack components — all with full CoA documentation.

View Research Catalogue →

Component 1: Tirzepatide — Dual Incretin Axis Modulation

⚠️ POM — Research use only. Prescription required for clinical use in the UK.

Tirzepatide is a 39-amino acid dual agonist of GLP-1R (glucagon-like peptide-1 receptor) and GIPR (glucose-dependent insulinotropic polypeptide receptor). Its metabolic effects in the published clinical literature are among the most substantial of any pharmacological intervention studied for obesity and type 2 diabetes:

  • Appetite suppression: GLP-1R activation in the hypothalamus and brainstem reduces food intake by modulating satiety signalling — the primary driver of caloric deficit in clinical studies. GIP-R co-activation appears to enhance this effect beyond what GLP-1R agonism alone produces
  • Incretin-enhanced insulin secretion: Both GLP-1R and GIP-R are expressed on pancreatic beta cells and stimulate glucose-dependent insulin release — reducing postprandial glucose spikes without hypoglycaemia risk at physiological glucose levels
  • Adipose tissue lipolysis: GIP-R signalling in adipocytes has been shown to promote triglyceride uptake under fed conditions and lipolysis under fasted conditions — a direct effect on adipose biology independent of caloric intake modulation
  • Anti-inflammatory effects: GLP-1R activation suppresses NF-κB and reduces M1 macrophage polarisation in preclinical models — relevant to the chronic low-grade inflammation driving insulin resistance in metabolic disease

SURMOUNT-1 (Jastreboff et al., NEJM 2022, n=2539) documented 22.5% mean weight loss at 72 weeks with 15 mg Tirzepatide — the highest weight loss efficacy reported for any approved pharmacological agent in obesity trials to date. The SURPASS trial series established its HbA1c and weight reduction superiority over semaglutide, insulin, and other comparators in T2D.

Component 2: Tesamorelin — GHRH-Mediated Visceral Fat Reduction

Tesamorelin (CAS: 218949-48-5; brand name Egrifta) is a synthetic analogue of GHRH(1-44) modified with a trans-3-hexenoic acid group at the N-terminus to improve stability against DPP-IV degradation. It is the first and only GHRH analogue to receive FDA approval (2010) — specifically for the treatment of HIV-associated lipodystrophy, a condition characterised by pathological accumulation of visceral adipose tissue (VAT).

Tesamorelin’s mechanism: GHRH-R agonism → Gαs → ↑cAMP → PKA → GH secretion → hepatic IGF-1 production. Unlike directly injected GH, Tesamorelin works through the physiological GH axis and preserves pulsatile GH dynamics. The visceral fat reduction appears to be mediated by GH’s direct lipolytic effect on VAT — GH receptors are more densely expressed in visceral than subcutaneous adipose tissue, explaining the depot-selective effect.

Key clinical data from the Tesamorelin registration trials (Falutz et al., 2010, J Clin Endocrinol Metab):

  • Visceral adipose tissue reduced by approximately 18% vs placebo at 26 weeks (2 mg SC daily) in HIV lipodystrophy subjects
  • Trunk fat (DXA measurement) significantly reduced; limb fat minimally affected — confirming visceral selectivity
  • IGF-1 levels elevated approximately 1.5–2× above baseline — confirming GH axis activation
  • No significant change in glucose metabolism or insulin sensitivity at therapeutic doses — a key safety finding
  • Lipid improvements: triglycerides ↓ ~15%, HDL cholesterol modestly improved

In the metabolic research stack context, Tesamorelin’s GH-axis-mediated VAT reduction pathway is distinct from both Tirzepatide’s appetite/incretin mechanism and AOD-9604’s direct adrenergic lipolysis. A combined protocol would potentially address three different mechanistic contributors to visceral adiposity simultaneously.

Research Context — Why Visceral Fat Is the Target: Visceral adipose tissue (VAT) — the fat depot surrounding abdominal organs — is metabolically and clinically distinct from subcutaneous fat. VAT adipocytes are larger, more metabolically active, more lipolytically responsive, and more deeply connected to the hepatic portal circulation. Free fatty acids released from VAT flow directly to the liver, driving hepatic insulin resistance, steatosis, and dyslipidaemia. Reducing VAT therefore has downstream metabolic benefits that reducing subcutaneous fat does not — which is why Tesamorelin’s VAT-selective reduction in HIV lipodystrophy was clinically significant despite modest total body weight change. The Metabolic Research Stack targets VAT reduction through three independent mechanisms: Tirzepatide via appetite/insulin (global fat reduction), Tesamorelin via GH-axis lipolysis (VAT-selective), and AOD-9604 via β3-AR (direct adipocyte lipolysis).

Component 3: AOD-9604 — Direct β3-AR Lipolysis Independent of IGF-1

AOD-9604 (Advanced Obesity Drug; CAS: 221231-10-3; MW: 1817.1 Da) is a synthetic analogue of the C-terminal fragment of human growth hormone (residues 176–191 of the 191-aa GH sequence), modified with a tyrosine at the N-terminus. Its defining research characteristic is that it retains GH’s lipolytic activity while producing zero IGF-1 elevation at any dose studied — separating the two primary effects of native GH into independent compounds.

AOD-9604 mechanism: direct β3-adrenergic receptor (β3-AR) agonism on adipocytes → Gαs → ↑cAMP → PKA → hormone-sensitive lipase (HSL) activation → triglyceride hydrolysis → free fatty acid release. This pathway is:

  • Independent of GH receptor: AOD-9604 does not bind the full-length GH receptor and does not activate the JAK2/STAT5 pathway (the primary GH receptor signalling cascade responsible for IGF-1 induction)
  • Independent of insulin: β3-AR lipolysis does not require insulin signalling — it is active even under insulin-resistant conditions, making it potentially valuable in metabolic disease research models where insulin sensitivity is impaired
  • Independent of incretin axis: AOD-9604’s lipolytic activity operates entirely through adrenergic signalling, with no interaction with GLP-1R or GIP-R pathways — providing a third mechanistically independent route in the stack

The METAOD005 Phase IIb trial (n=300+, 24-week randomised controlled trial in overweight/obese subjects) tested seven AOD-9604 dose arms (0.25 mg to 30 mg daily). The 1 mg/day arm produced statistically significant fat mass reduction versus placebo; doses above 1 mg showed no additional fat loss, confirming a non-linear dose-response with saturation at moderate doses. No IGF-1 elevation was observed at any dose.

Tesamorelin and AOD-9604 research-grade supply from Pure Grade Labs — with full CoA and purity verification.

Browse Research Chemicals →

Metabolic Mechanism Matrix: Independent Pathways

Mechanism Tirzepatide Tesamorelin AOD-9604
Primary receptor GLP-1R + GIP-R GHRH-R β3-AR
Appetite suppression ✓ Central Minimal None
GH axis activation None direct ✓ GHRH-R/cAMP None
Direct lipolysis GIP-R adipocyte Via GH → HSL ✓ β3-AR → HSL
IGF-1 elevation None Yes (GH-mediated) None at any dose
Human clinical evidence Extensive (Phase III) FDA-approved (Phase III) Phase IIb (METAOD005)

Research Rationale — The Complementarity Principle: The Metabolic Research Stack exemplifies a principle increasingly applied in metabolic pharmacology: multi-pathway attack on a single biological problem. Obesity and visceral adiposity are not single-mechanism disorders — they involve dysregulated appetite, impaired insulin sensitivity, blunted GH secretion, reduced adrenergic tone in adipose tissue, and chronic inflammation. A single-mechanism intervention addresses one vector; a three-mechanism combination potentially addresses several simultaneously. Whether this translates into greater than additive fat loss in a preclinical model is the experimental question. The absence of co-administration data means the stack currently represents a well-reasoned hypothesis, not a validated protocol — which is precisely what makes it interesting research territory.

Research Design Considerations

  • Tirzepatide (POM): ~5-day half-life; once-weekly injection in clinical trials. Research protocols should confirm regulatory authorisation for POM-status compound use at the relevant institution
  • Tesamorelin: Short half-life (minutes without modification — though the trans-3-hexenoic acid group improves stability); once-daily injection protocol used in Egrifta clinical trials
  • AOD-9604: Short plasma half-life; the METAOD005 trial used daily subcutaneous injection. The 1 mg/day dose is the established research reference point
  • Endpoint selection: For fat mass, DXA or CT adipose tissue segmentation is the most validated endpoint. IGF-1, fasting insulin, and HOMA-IR provide metabolic context. For direct lipolysis studies, serum NEFA (non-esterified fatty acids) and glycerol are the primary readouts
  • Potential interaction caution: Tesamorelin’s IGF-1 elevation and AOD-9604’s zero-IGF-1 profile are in direct mechanistic contrast. Researchers studying the combination should include IGF-1 measurement as a key endpoint to determine whether AOD-9604 modifies Tesamorelin’s GH axis effects

Frequently Asked Questions

What makes this a metabolic research stack rather than a weight loss stack?

Each compound engages a distinct metabolic pathway — incretin axis (Tirzepatide), GH axis (Tesamorelin), and adrenergic lipolysis (AOD-9604) — making it a tool for studying multi-pathway metabolic regulation rather than a single-target intervention. The research value is in the mechanistic independence, not the aggregate fat-loss magnitude.

What is Tesamorelin’s clinical evidence base?

Tesamorelin is FDA-approved (Egrifta) based on Phase III trials in HIV lipodystrophy. Falutz et al. (2010) demonstrated ~18% visceral fat reduction vs placebo at 26 weeks with 2 mg daily SC injection, with preserved pulsatile GH dynamics, IGF-1 elevation ~1.5–2×, and no significant glucose metabolism impairment — the strongest clinical dataset for a GHRH analogue visceral fat reduction application.

Why does AOD-9604 not elevate IGF-1 even though it’s derived from GH?

AOD-9604 is the C-terminal 176–191 fragment of GH, which lacks the N-terminal domain required for GH receptor (GHR) binding and JAK2/STAT5 signalling — the pathway that induces IGF-1 production. AOD-9604 instead binds β3-adrenergic receptors directly, activating adipocyte lipolysis without any GHR interaction. This is confirmed by the METAOD005 trial: no IGF-1 elevation at any of the 7 dose levels tested.

Is Tirzepatide required for this stack to work in research?

No — Tesamorelin and AOD-9604 are independent research compounds with their own evidence bases. Tirzepatide adds the incretin/appetite dimension to the stack’s metabolic scope. Researchers in jurisdictions or institutions where POM-status compounds require additional approvals may run a Tesamorelin + AOD-9604 two-compound protocol while keeping the incretin component separate.

Summary

The Metabolic Research Stack represents the application of mechanistic non-redundancy to adipose biology research. Tirzepatide addresses appetite and insulin through the incretin axis with the strongest clinical weight loss evidence base of any approved pharmacology. Tesamorelin provides GH-axis-mediated visceral fat reduction with FDA-approved clinical data. AOD-9604 provides direct adrenergic lipolysis without GH axis activation, separating the lipolytic and anabolic components of native GH pharmacology. Three receptors, three second messenger systems, three independently documented fat reduction mechanisms — and no published co-administration trial to date. That gap is the research opportunity this stack is designed to investigate.

Source Tesamorelin, AOD-9604, and the full metabolic research range from Pure Grade Labs.

Shop Research Chemicals →

References

  1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. PMID: 35658024
  2. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503–515. PMID: 34170647
  3. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2349–2360. PMID: 18057339
  4. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat. J Clin Endocrinol Metab. 2010;95(9):4291–4304. PMID: 20554715
  5. Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab. 2000;279(3):E501–507. PMID: 10950819
  6. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274–278. PMID: 11146367

Disclaimer: This article is published for educational and research purposes only. Tirzepatide is a Prescription Only Medicine (POM) in the United Kingdom sold strictly as a research chemical for qualified research use. Tesamorelin and AOD-9604 are sold as research chemicals for laboratory investigation only. No medical claims are made for any component of this stack. This article does not constitute medical advice, a treatment recommendation, or a clinical protocol. Consult a qualified healthcare professional for any clinical application.